Life Insurance Corporation of India (LICI.NS) — Valuation Snapshot

Life Insurance Corporation of India (LICI.NS) is a bank, insurer or other financial, and a free-cash-flow discounted-cash-flow (DCF) model is structurally the wrong lens for it: for these businesses debt and float are raw material, not financing, so there is no meaningful 'free cash flow' to discount. Instead of a misleading intrinsic-value number, this page reads LICI.NS the way financials are actually valued — on relative multiples such as price-to-earnings and, above all, price-to-book — plus a plain description of where the stock trades. It is a descriptive snapshot, not a valuation, and not investment advice.

On the numbers we do have, LICI.NS trades at a recent price of ₹399.00, a market capitalisation of about ₹2,523,674,181,632, sitting 36% of the way up its 52-week range (₹360.75–₹465.95), on the NSE.

The standard alternative to a DCF is relative valuation — comparing LICI.NS's trading multiples against a sector benchmark. Here that gives P/E of 8.1× (cheaper than the peer median of 14.0×); Fwd P/E of 6.8× (cheaper than the peer median of 13.4×); P/B of 3.0× (richer than the peer median of 2.6×); P/S of 0.2× (cheaper than the peer median of 4.8×); Dividend yield of 2.5% (cheaper than the peer median of 1.9%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.

The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. LICI.NS shows a price-to-book (P/B) of 2.99 and book value of ₹133.39 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.

Finally, a price-based read — explicitly not a valuation. LICI.NS is in a mixed trend, trading -14.4% from its 52-week high. Over the past year the stock is -11.8%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.

To be exact about what this page is not: we are not saying the numbers for LICI.NS are unavailable. They are, and they are above. We are saying a discounted-cash-flow model is the wrong instrument for this kind of business, and publishing one anyway — because the inputs happen to exist — would be a precise answer to the wrong question. Refusing is the more useful answer, and it is the same rule we apply to every name in this category.